Selumetinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Selumetinib: Familial generalized lentiginosis
One-Sentence Summary
Selumetinib is a MEK1/2 inhibitor originally used for neurofibromatosis. The TxGNN model predicts it may be effective for peripheral nerve schwannoma, the best-supported of its top 10 predictions. The evidence is early-stage: 3 clinical trials (one terminated, two not yet recruiting) and 6 publications, mostly reviews, preclinical work and case reports.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Familial generalized lentiginosis |
| TxGNN Prediction Score | 0.9996 |
| Evidence Level | L5 (as assigned in the compiled data; note that no completed Phase 2/3 RCT exists, so this is generous) |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold (pending further evidence; see Conclusion) |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not currently available in the compiled data. Based on known pharmacology, selumetinib is a MEK1/2 inhibitor that blocks the RAS/RAF/MEK/ERK signalling pathway.
In neurofibromatosis, loss of NF1 or NF2 leads to hyperactivation of this pathway in Schwann cells, driving nerve sheath tumour growth. Selumetinib is already approved for NF1 plexiform neurofibromas, a closely related nerve sheath tumour. Schwannomas arise from the same cell lineage and share this signalling dependence, particularly in NF2-related schwannomatosis (NF2-SWN). This gives a plausible mechanistic basis for the prediction.
Reviews and preclinical work in the compiled literature are consistent with this idea. However, efficacy in schwannoma itself has not been demonstrated in a completed study.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03095248 | Phase 2 | Terminated | 10 | Selumetinib in NF2-related tumours, assessing tumour growth and hearing changes. Directly relevant design, but terminated early with very limited data |
| NCT07707947 | Phase 2 | Not yet recruiting | 20 | Single-centre, single-arm study of selumetinib in adults and children with inoperable or progressive NF2-SWN. No results yet |
| NCT07713745 | Phase 2 | Not yet recruiting | 200 | PRIME-NF2 adaptive platform-basket trial of novel agents in NF2-SWN (vestibular and non-vestibular schwannomas, meningiomas, ependymomas). Unclear whether selumetinib is included |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37906356 | 2023 | Review | Current Oncology Reports | Management of nervous system tumours in neurofibromatosis; discusses MEK inhibitors as an advance |
| 37046591 | 2023 | Review/Expert consensus | Cancers | EURACAN recommendations for peripheral and cranial nerve tumours; evidence described as particularly low owing to rarity |
| 38058737 | 2023 | Case report | Mol Ther Methods Clin Dev | Partial response to selumetinib in a patient with NF2-associated ependymoma |
| 38216572 | 2024 | Preclinical | Nature Communications | Interactions between NF1 and NF2 tumour suppressors in Schwann cell tumour de-differentiation and treatment resistance |
| 33835000 | 2020 | Case report | Acta Dermatovenerol Croat | Plexiform neurofibroma occurring without NF1 |
| 40861330 | 2025 | Case report | Surgical Case Reports | Surgical management of a giant mediastinal schwannoma in NF1; not about selumetinib |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02530147 | KOSELUGO | Not specified | Not specified |
| 02530139 | KOSELUGO | Not specified | Not specified |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (MEK1/2 inhibitor), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: 84 interactions were recorded. Major-level interactions in the listed entries include:
- Aprepitant
- Dexamethasone
- Clarithromycin
- Cobicistat
Moderate-level interactions include several antithrombotic and antiplatelet agents (e.g., acetylsalicylic acid, apixaban, abciximab, bivalirudin, cilostazol, dipyridamole), as well as cimetidine, clotrimazole and deferasirox.
Package insert warnings and contraindications were not available; please refer to the Health Canada package insert for these.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale is strong, and selumetinib is already marketed in Canada for a related nerve sheath tumour. However, evidence in schwannoma consists of one terminated 10-patient Phase 2 trial, two trials not yet recruiting, and a case report in ependymoma. No completed efficacy dataset exists. The other nine top predictions have little or no supporting evidence. Rhabdoid tumour has only indirect preclinical and umbrella-trial support.
To proceed, the following is needed:
- Results or data from the terminated NCT03095248 trial
- Confirmation of whether selumetinib is included in PRIME-NF2, and follow-up on NCT07707947 once it recruits
- Package insert warnings and contraindications from Health Canada (needed for safety screening)
- Mechanism-of-action data from DrugBank
- A review of Major drug interactions (e.g., strong CYP3A4 inhibitors) for the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.